Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial
Simon P. Bach, D. Sebag-Montefiore, Victoria Homer, Alexandra Gilbert et autres
gb, nl, se, dk, be, us (code pays fourni par la source)
0 citations
The Lancet Oncology